A placebo and active comparator-controlled trial of rofecoxib for the treatment of rheumatoid arthritis

Abstract

Rofecoxib 25 mg once daily had similar efficacy to naproxen 500 mg twice daily (a standard dose). No additional benefit was seen with 50 mg rofecoxib.